ABBOTT PARK, Ill., April 14, 2015
/PRNewswire/ -- Today, Abbott (NYSE: ABT) and Sekisui
announce an agreement to offer coagulation testing solutions for
laboratories worldwide. Coagulation tests measure a person's blood
clotting ability, which can help doctors assess risks of excessive
bleeding or developing clots. Under the agreement, Abbott will be
the exclusive distributor of Sekisui's new CP3000 coagulation
instrument in the United States,
Europe and other regions that
recognize CE Mark.
"Abbott is committed to providing testing solutions that
healthcare providers rely on for actionable information in
diagnosing and treating various medical conditions," said
Jaime Contreras, senior vice
president, Commercial Operations, Diagnostics, Abbott.
"Collaborating with Sekisui broadens our offerings within
hematology, providing an important component needed to improve care
for people around the world."
Coagulation testing helps clinicians in assessing people before
many medical treatments and in monitoring those who take
medications that can affect clotting. It is also useful in the
diagnosis of blood-related disorders, such as hemophilia (when
blood does not clot normally) and thrombosis (formation of a clot
that blocks blood flow).
"Coagulation testing has been an important focus for Sekisui for
over twenty years," said Robert
Schruender, president and chief operating officer of Sekisui
Diagnostics. "We are delighted that this relationship with Abbott
will bring the benefits of our system, which is a leading product
in Japan, to many customers around
the world."
"Collaborating with Sekisui broadens our offerings
within hematology, providing an important component needed to
improve care for people around the world."
JAIME CONTRERAS, SENIOR
VICE PRESIDENT, COMMERCIAL OPERATIONS, DIAGNOSTICS,
ABBOTT
Sales of the CP3000 are expected to begin later this year in
Europe, countries that recognize
CE Mark and non-regulated countries, and in the United States in 2016. Abbott will have
non-exclusive distribution rights with Sekisui in China, Hong
Kong, Japan and
Macau.
About the CP3000:
The Sekisui CP3000 system features high-quality reagents, small
sample volume requirements and offers a combination of
high-throughput and a compact footprint. With a broad assay menu
and rapid result turnaround time, the CP3000 can rapidly meet the
workflow needs of laboratories of all sizes, while providing high
quality and reliable results. The system will aim to seamlessly
connect to Abbott's ACCELERATOR a3600 lab automation platform and
middleware solutions.
About Sekisui:
Sekisui Medical (SMD) headquartered in Tokyo, Japan, aspires to become a leading
global medical company in fields such as Diagnostics,
Pharmaceuticals & Fine Chemicals, and ADME & Toxicology
Research. The Diagnostics business is engaged in the development,
manufacture and distribution of commercial plastic vacuum blood
collection tubes, and various in vitro diagnostics products
and systems, including coagulation.
Sekisui Diagnostics, a global diagnostics company
and sister company of SMD, is committed to improving patient's
lives by providing innovative medical diagnostics to physicians and
laboratories through a global commercial network. Product lines
include clinical chemistry and coagulation systems, reagents,
infectious disease testing and rapid test kits, as well as enzymes
and specialty bio-chemicals.
About Abbott:
Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the
breadth of healthcare. With a portfolio of leading, science-based
offerings in diagnostics, medical devices, nutritionals and branded
generic pharmaceuticals, Abbott serves people in more than 150
countries and employs approximately 73,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at
@AbbottNews.
Photo -
http://photos.prnewswire.com/prnh/20150414/198389
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbott-and-sekisui-collaborate-to-offer-coagulation-testing-for-laboratories-worldwide-300065259.html
SOURCE Abbott